KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Finished Goods: 2017-2021

Historic Finished Goods for Aquestive Therapeutics (AQST) over the last 3 years, with Mar 2021 value amounting to $1.0 million.

  • Aquestive Therapeutics' Finished Goods rose 42.80% to $1.0 million in Q1 2021 from the same period last year, while for Mar 2021 it was $1.0 million, marking a year-over-year increase of 42.80%. This contributed to the annual value of $544,000 for FY2020, which is 4.82% up from last year.
  • Latest data reveals that Aquestive Therapeutics reported Finished Goods of $1.0 million as of Q1 2021, which was up 84.01% from $544,000 recorded in Q4 2020.
  • In the past 5 years, Aquestive Therapeutics' Finished Goods ranged from a high of $1.3 million in Q2 2018 and a low of $519,000 during Q4 2019.
  • Its 3-year average for Finished Goods is $865,889, with a median of $858,000 in 2020.
  • Per our database at Business Quant, Aquestive Therapeutics' Finished Goods plummeted by 56.13% in 2019 and then surged by 42.80% in 2021.
  • Quarterly analysis of 5 years shows Aquestive Therapeutics' Finished Goods stood at $1.1 million in 2017, then climbed by 11.18% to $1.2 million in 2018, then slumped by 56.13% to $519,000 in 2019, then rose by 4.82% to $544,000 in 2020, then spiked by 42.80% to $1.0 million in 2021.
  • Its Finished Goods stands at $1.0 million for Q1 2021, versus $544,000 for Q4 2020 and $858,000 for Q3 2020.